GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Cyclically Adjusted FCF per Share

Biogen (BSP:BIIB34) Cyclically Adjusted FCF per Share : R$17.85 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biogen's adjusted free cash flow per share for the three months ended in Mar. 2024 was R$2.449. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$17.85 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biogen's average Cyclically Adjusted FCF Growth Rate was 9.70% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 21.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Biogen was 157.10% per year. The lowest was 11.30% per year. And the median was 25.70% per year.

As of today (2024-05-15), Biogen's current stock price is R$171.36. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$17.85. Biogen's Cyclically Adjusted Price-to-FCF of today is 9.60.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogen was 107.99. The lowest was 9.07. And the median was 32.38.


Biogen Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted FCF per Share Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.29 13.22 16.59 16.49 16.78

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.45 17.26 17.44 16.78 17.85

Competitive Comparison of Biogen's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.



Biogen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.449/129.4194*129.4194
=2.449

Current CPI (Mar. 2024) = 129.4194.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 1.449 100.560 1.865
201409 1.394 100.428 1.796
201412 1.480 99.070 1.933
201503 1.406 99.621 1.827
201506 2.011 100.684 2.585
201509 1.838 100.392 2.369
201512 3.061 99.792 3.970
201603 2.408 100.470 3.102
201606 2.305 101.688 2.934
201609 1.749 101.861 2.222
201612 3.588 101.863 4.559
201703 -1.996 102.862 -2.511
201706 2.182 103.349 2.732
201709 3.312 104.136 4.116
201712 3.153 104.011 3.923
201803 3.220 105.290 3.958
201806 2.520 106.317 3.068
201809 5.220 106.507 6.343
201812 5.376 105.998 6.564
201903 4.312 107.251 5.203
201906 5.974 108.070 7.154
201909 5.958 108.329 7.118
201912 6.484 108.420 7.740
202003 5.649 108.902 6.713
202006 9.868 108.767 11.742
202009 6.255 109.815 7.372
202012 -2.594 109.897 -3.055
202103 4.154 111.754 4.811
202106 6.425 114.631 7.254
202109 4.384 115.734 4.902
202112 4.899 117.630 5.390
202203 0.582 121.301 0.621
202206 3.999 125.017 4.140
202209 3.618 125.227 3.739
202212 -1.571 125.222 -1.624
202303 2.285 127.348 2.322
202306 2.215 128.729 2.227
202309 2.858 129.860 2.848
202312 -0.294 129.419 -0.294
202403 2.449 129.419 2.449

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Biogen  (BSP:BIIB34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=171.36/17.85
=9.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogen was 107.99. The lowest was 9.07. And the median was 32.38.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biogen Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BSP:BIIB34) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines